Business
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in pos
About this update from Entera Bio Ltd.
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today reported comparative Phase 1 data evaluating single-tablet and multi-tablet oral EB613 with Forteo® (teriparatide SC injection, Eli Lilly). The oral presentation “Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study” was presented by Clinical Pharmacologist Helen S. Pentikis, PhD, as a Late-Breaking Oral Presentation at ENDO 2026, the annual meeting of the Endocrine Society, taking place in Chicago, Illinois. Substantial evidence supports the use of anabolic (bone-building) therapies over anti-resorptive drugs for rapidly lowering fracture risk in osteoporosis patients at high risk of fractures. However, the three approved agents (Forteo®, Tymlos®, Evenity®) require daily or monthly injections and are used in only a minority of eligible patients. Entera is developing EB613 as the first oral, anabolic tablet treatment for patients with osteoporosis. In the Phase 1 (NCT05965167) study, a cohort of 15 healthy participants each received single-tablet EB613, multi-tablet oral EB613, and subcutaneous Forteo® at doses ranging from 1 mg to 3 mg, to evaluate and compare the three treatments’ pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Key findings included: “Our ability to simplify the proposed dosing regimen for patients from the multi-tablet presentation of EB613, which was shown to be safe and effective in our Phase 2 osteoporosis study, to a single daily tablet is a significant scientific achievement. A single daily oral PTH tablet (EB613) could make anabolic treatment far more acceptable to many patients and health care providers and have a substantial impact towa...